Skip Navigation

Kit Check’s Bluesight for Controlled Substances™ Named Category Leader for Drug Diversion Monitoring in 2020 Best in KLAS Report

KLAS report ranks Kit Check as the top performer with 93.9 rating for consistently delivering on product support, customer loyalty and quality of operations.  

WASHINGTON (January 31, 2020) — Kit Check™, the leader in automated and intelligent medication management solutions, today announced that its Bluesight™ for Controlled Substances diversion detection software has been named the Category Leader in Drug Diversion Monitoring by leading analyst firm KLAS Research. The first-ever Best in KLAS report to include next-generation medication diversion products, “Best in KLAS 2020 Software & Services” highlights hospitals and health systems’ need for drug diversion monitoring technology amid the opioid epidemic.

“In our quest for full medication visibility and increased medication intelligence, being recognized by our customers as a Category Leader in the 2020 Best in KLAS report is an incredibly meaningful validation of our work,” said Kevin MacDonald, CEO and co-founder of Kit Check. “KLAS’s report recognizes that although progress has been made, the issue of drug diversion grows in its significance within the hospital setting. We are proud and humbled by the positive feedback from KLAS and our customers.”

Kit Check’s Bluesight for Controlled Substances earned the overall top category score of 93.9 out of 100, based on customer feedback across a range of areas including culture, loyalty, operations, product, relationship, and value. In addition, 100 percent of Kit Check customers reported they would invest in the Bluesight for Controlled Substances product again, and 100 percent said Bluesight for Controlled Substances is part of their long-term plan within their facility or system.

Other key findings from the inaugural report showed:

  • Bluesight for Controlled Substances works as promoted (8.4/9 rating)
  • Kit Check offers high quality support (8.6/9 rating)
  • The Bluesight for Controlled Substances solution drives tangible outcomes for health facilities (8.1/9 rating)

KLAS includes customer comments in its report, and those for Bluesight for Controlled Substances were overwhelmingly positive:

“I am very eager to recommend Kit Check; they have been really great at helping us network across the country and giving us some connections that we may not have had otherwise. Those connections have helped us develop our diversion network, and we can connect with some sister sites to see whether we are seeing the same things.”

“I am optimistic that my satisfaction will stay high. The vendor reaches out when they are developing new things and want us to test them, and I can appreciate that. They don’t just have us go live with something and pray for the best. They want to see how it is going to work with what we do in our hospital, and that is almost unheard of when it comes to software.”

To determine these industry-wide rankings, KLAS utilizes both performance data and customer satisfaction ratings gathered in interviews with healthcare executives across the country. According to the data KLAS collected, Kit Check customers report having a strong experience overall with the next-generation software and noted its ease of use and integration tools that help users document investigation findings.

With diversion being a top concern across the healthcare continuum, Kit Check recently partnered with Omnicell to offer Bluesight for Controlled Substances to even more hospitals and health care facilities. Both Bluesight for Controlled Substances and Omnicell were recognized in the KLAS Research 2019, “Drug Diversion Monitoring 2019, An Early Look at Emerging vs. Established Technology.”

“Providers and payers demand better performance, usability, and interoperability from their vendor partners every year,” said Adam Gale, KLAS President. “Best in KLAS winners set the standard of excellence in their market segment. Earning a Best in KLAS award should both excite and humble the recipients. It serves as a signal to providers that they should expect only the best from the winning vendors.”

The full report is available at   

To learn more about Kit Check’s solutions, please visit

To learn more about KLAS, please visit

About Kit Check
Kit Check is the leading provider of automated medication management solutions for hospital pharmacies. Our solutions blend powerful machine learning and advanced tracking technology to streamline medication inventory, workflow, and auditing processes, and help hospital pharmacies cut costs, reduce risk, and get more done. To date, our more than 500 U.S. and Canadian hospital partners have tracked more than 90 million medications using Kit Check’s RFID product. Bluesight™ for Controlled Substances software is currently in use in more than 100 hospitals including full health system implementations, with more than 6 million cases tracked. More information about Kit Check and our software solutions can be found at

About KLAS
KLAS is a research and insights firm on a global mission to improve healthcare delivery by amplifying the provider’s voice. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software, services and medical equipment to deliver timely reports, trends and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving vendor performance.

Jill Gross
Matter Health for Kit Check